logo-loader

Theralase Technologies' cancer treatment shows positive in-vivo results

Last updated: 18:26 29 Nov 2011 GMT, First published: 19:26 29 Nov 2011 GMT

no_picture_pai

Theralase Technologies (CVE:TLT) said Tuesday that its Photo Dynamic Compounds (PDC) have managed to locally destroy cancerous tumour cells in an in-vivo model, or a living organism.

The results now confirm what was initially seen in in-vitro cancer cell lines model, which is a high kill rate of cancer cells when exposed to Theralase's patented light-activated PDCs.

"It was critical to establish the relevance of prior successful in-vitro destruction for three cancer cell lines at greater than 99% efficacy to a subcutaneous in-vivo tumour model to see if similar results could be achieved," commented senior scientist at the Ontario Cancer Institute, Princess Margaret Hospital, Dr. Lothar Lilge.

Theralase said it plans to aggressively pursue commercialization for its PDC technology through the accelerated FDA regulatory approval process.

In a statement, chief scientific officer, Arkady Mandel, said: “This is a very significant milestone in our research and development path, proving Theralase's PDCs can achieve local destruction of malignant tumour in-vivo."

Chief executive, Roger Dumoulin-White, added: "This is an important milestone for the company because we have now demonstrated the ability of the patented PDCs to destroy cancer cells in both an in-vitro and in an in-vivo cancer model, when light activated."

"Theralase is well on its way to prove the viability of its technology to increase the oncologist's options for a successful treatment of cancer."

The company said it intends to present results at the annual International Society for Optics and Photonics conference in 2012.

Theralase also said Tuesday that revenues rose 6.7 percent to $453,212 for the three months that ended September 30, up from $424,879 a year ago.

Theralase, found in 1995, makes and develops superpulsed lasers used for biostimulation as well as bio-destruction applications. It products are used to treat chronic pain, neural muscular-skeletal conditions and wound healing.